MetaCap

IDEAYA Biosciences (IDYA) vs MBX Biosciences (MBX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MBX Biosciences (MBX) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 83.0% versus a loss of 24.8%. IDEAYA Biosciences is the larger company by market cap ($2.47 billion vs $2.46 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%MBX+82.98%
+170%+68%-34%
Nov 21, 20251 yearNov 20, 2026
IDYA-31.77%MBX+109.51%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus MBX key metrics
MetricIDYAMBX
Share price$25.56$49.55
Market cap$2.47B$2.46B
1-day change-2.33%-7.23%
YTD return-26.06%+57.10%
1-year return-24.80%+82.98%
5-year return+7.35%—
EPS (TTM)$-4.50$-3.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M—
Revenue growth (YoY)+3024.43%—
Net income (latest FY)$-113.70M$-87.00M
Operating margin-72.84%—
Net margin-51.99%—
52-week high$42.68$72.64
52-week low$25.46$26.14
Distance from 52-week high-40.11%-31.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+98.32%+91.91%
Average volume933.58K532.80K
Shares outstanding96.69M49.66M
Employees14563
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MBX has outperformed IDYA by 107.8 percentage points over the past year.

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

IDYA vs MBX FAQ

Which is bigger, IDEAYA Biosciences or MBX Biosciences?

IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $2.47B compared with $2.46B for MBX Biosciences (MBX).

Which stock has performed better over the past year, IDYA or MBX?

MBX returned +82.98% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and MBX Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons